MCF Advisors’s ImmunityBio IBRX Stock Holding History

MCF Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.2K	Hold	2,646	–	–	﹤0.01%	866
2026 Q1	$20.3K	Buy	2,646 +500	+23%	+$3.42K	﹤0.01%	817
2025 Q4	$4.25K	Hold	2,146	–	–	﹤0.01%	973
2025 Q3	$5.28K	Buy	+2,146	New	+$5.53K	﹤0.01%	792

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MCF Advisors's IBRX Position: Q2 2026 in Review

MCF Advisors held its ImmunityBio (IBRX) position steady in Q2 2026 at 2,646 shares worth $23.2K. The position accounts for ﹤0.01% of the portfolio, ranked #866.

MCF Advisors first reported a position in IBRX in Q3 2025 and has held it in 4 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

MCF Advisors held 2,646 shares of ImmunityBio worth $23.2K as of Q2 2026.
MCF Advisors left its ImmunityBio share count unchanged in Q2 2026.
ImmunityBio made up ﹤0.01% of MCF Advisors's portfolio in Q2 2026, its #866 holding.
MCF Advisors first reported a position in ImmunityBio in Q3 2025 and has held it in 4 quarters since.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on MCF Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.